Aarti Drugs Ltd
NSE:AARTIDRUGS
Aarti Drugs Ltd
NSE:AARTIDRUGS
Price:
352.9
INR
-0.62%
Market Closed
Market Cap:
₹32.2B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Aarti Drugs Ltd
NSE:AARTIDRUGS
|
IN |
Multiples-Based Value
The Multiples-Based Value of one
AARTIDRUGS
stock under the Base Case scenario is
634.62
INR.
Compared to the current market price of 352.9 INR,
Aarti Drugs Ltd
is
Undervalued by 44%.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
AARTIDRUGS
Multiples-Based Value
634.62
INR
Undervaluation 44%
Multiples Across Competitors
AARTIDRUGS Competitors Multiples
Aarti Drugs Ltd Competitors
Aarti Drugs Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IN |
|
Aarti Drugs Ltd
NSE:AARTIDRUGS
|
32.2B INR | 1.3 | 15.9 | 11.5 | 14.3 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
878.2B USD | 13.5 | 42.6 | 28.7 | 30.6 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
573B USD | 6.1 | 21.4 | 14.9 | 18.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.6 | 11.6 | 13.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
232.5B GBP | 5.2 | 30 | 16.6 | 23.4 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
297.3B USD | 4.6 | 16.3 | 10.1 | 12.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
231.4B CHF | 5.1 | 20.7 | 12.8 | 16.5 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.6 | 10.8 | 8 | 9.3 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
155.5B USD | 2.5 | 20 | 7.7 | 10.2 | |
| UK |
|
GlaxoSmithKline PLC
LSE:GSK
|
88.4B GBP | 2.7 | 15.5 | 8.4 | 10.4 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
